AbbVie Inc. Website

AbbVie Inc.

NYSE-ABBV

Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

  • Name

    AbbVie Inc.

  • CEO

    Robert A. Michael

  • Website

    www.abbvie.com

  • Sector

    Biotechnology

  • Year Founded

    2012

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • AbbVie's dividend yield should act as valuation support, as the cash flows to support the dividend look secure over the next several years.

  • AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and physician entrenchment.

  • AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira.

Bears Say

  • AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.

  • AbbVie's Cerevel acquisition saw a setback with the failure of two phase 2 studies for key schizophrenia drug candidate emraclidine.

  • AbbVie's aesthetics business makes the firm more vulnerable to swings in the economy than other biopharma firms, putting pressure on growth when consumer sentiment is low.

Source: Morningstar Analysis - Nov 03, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

AbbVie Inc. Faces Mixed Signals Amidst Stagnant Stock Performance

  • HSBC upgrades AbbVie to a Buy rating, raising the price target from $225 to $265.
  • FDA approvals for new treatments bolster investor confidence in AbbVie's innovation efforts.
  • Competitive pressures emerge with generic drug approvals impacting established products.

Over the past month, AbbVie Inc. (ABBV) demonstrated stagnant performance, closing with an overall movement of 0.0%. This lack of significant change occurred despite several bullish developments during this period. Notably, HSBC upgraded AbbVie to a Buy rating on December 10 and raised its price target from $225 to $265 due to solid growth momentum and effective execution within the company. The analysis indicated that competition from other drugs would not pose substantial risks to AbbVie's market position.

In addition, several FDA approvals for new treatments enhanced positive outlooks for the company. These included EPKINLY for relapsed or refractory follicular lymphoma and LUPRON DEPOT® for advanced prostate cancer, underscoring AbbVie's commitment to innovation in oncology and urology sectors. Furthermore, analysts at Scotiabank initiated coverage with a Sector Outperform rating while setting an ambitious price target at $280 per share—an endorsement reflecting strong confidence in AbbVie's future prospects.

However, bearish sentiments also emerged as competitive pressures mounted against some of AbbVie's established products. For instance, Amneal Pharmaceuticals received FDA approval for a generic version of Restasis—a direct competitor affecting potential revenue streams in ophthalmology markets. Additionally, discussions surrounding advancements made by Chinese biotechs raised concerns about increased competition within clinical trials related to CAR-T therapies and antibody-drug conjugates.

Despite these mixed signals characterized by promising product launches alongside emerging competitive threats, AbbVie’s stock performance lagged behind broader market trends; it underperformed relative to the S&P 500's return of 0.7%, resulting in an underperformance of -0.7%. Moreover, it trailed behind sector benchmarks as well; specifically, Abbott Inc underperformed the Health Care (XLV) sector by -1.9%.

NYSE:ABBV